ARCT — Arcturus Therapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00- $350.12m
- $113.09m
- $152.31m
- 33
- 35
- 38
- 27
Annual income statement for Arcturus Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.54 | 12.4 | 206 | 167 | 152 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 81.1 | 215 | 194 | 211 | 248 |
| Operating Profit | -71.5 | -203 | 12.2 | -44.3 | -95.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -72.1 | -204 | 10.6 | -27.9 | -80.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -72.1 | -204 | 9.35 | -29.7 | -80.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -72.1 | -204 | 9.35 | -29.7 | -80.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -72.1 | -204 | 9.35 | -29.7 | -80.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.55 | -7.74 | 0.345 | -1.95 | -3 |